A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A (Abstract) (LDN, low dose naltrexone)

Orphanet J Rare Dis
16 October 2021
https://pubmed.ncbi.nlm.nih.gov/34656144/

Annalisa talks about Low Dose Naltrexone (LDN), Trigeminal Nerve pain and Lyme disease (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Annalisa shares her Low Dose Naltrexone (LDN), Trigeminal Nerve pain and Lyme disease story and how it help change her life.

Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Use of LDN for Chronic Pain - Sahar Swidan, PHARM.D., ABAAHP, FAARFM, FACA (2021 Conference) (LDN, low dose naltrexone)

This talk is on the use of LDN for chronic pain. She reviews LDN’s actions in the CNS and the PNS, the immunomodulating effect of LDN, and some clinical trials on the use of LDN.

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

Henoch-Schonlein Purpura - Sally Daughtrey, ND (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Daughtry explains Henoch-Schonlein (HSP), its triggers and complications (such as serious hidden infections often missed initially), and the use of Low Dose Naltrexone in treating HSP. Dr. Daughtry gives an in-depth look into one pediatric case she treated successfully with LDN.

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)